One of the major Italian universities has developed new drugs that can be used in the treatment and/or in the prevention of inflammatory chronic intestinal diseases. The main advantage is that, differently from the drugs in use, the patented molecules act directly on the molecular cause of the disease and not only on the symptoms. In addition they have an endogenous origin and are delivered orally. The university is seeking either a license or a technical cooperation agreement with companies.
For further information, please contact:
Bio-Health Sector Tecnical Responsible